Skip to content
中文产业新闻评分63Chinese source

BOVenⅡ期延长随访显示泽布替尼联合方案一线治疗TP53突变MCL最佳uMRD6率达85%

钱正子教授：最佳uMRD6率达85%、停药后91%维持完全缓解——泽布替尼联合方案为TP53突变MCL带来深度缓解新策略

Original articleChinese edition

No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.